KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$183,444 | -$126,644 | -$92,907 | -$82,339 |
| Dep. & Amort. | $941 | $816 | $718 | $743 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $21,915 | $9,922 | $0 |
| Change in WC | $15,035 | $15,167 | $7,413 | -$12,322 |
| Other Non-Cash | $14,561 | -$485 | -$407 | $15,784 |
| Operating Cash Flow | -$152,907 | -$89,231 | -$75,261 | -$78,134 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$929 | -$42 | -$1,196 | -$931 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$30,571 | -$189,231 | -$98,246 | -$136,920 |
| Inv. Sales/Matur. | $122,524 | $104,955 | $140,857 | $195,711 |
| Other Inv. Act. | $0 | -$401 | $0 | $0 |
| Investing Cash Flow | $91,024 | -$84,719 | $41,415 | $57,860 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $98,040 | $0 | $0 | $0 |
| Stock Issued | $61,687 | $96,945 | $56,582 | $1,581 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $53,769 | $1,534 | $0 |
| Financing Cash Flow | $159,727 | $150,714 | $58,116 | $1,581 |
| Forex Effect | $1,982 | -$1,213 | $1,236 | -$1,167 |
| Net Chg. in Cash | $99,826 | -$24,449 | $25,506 | -$19,860 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $31,789 | $56,238 | $30,732 | $50,592 |
| End Cash | $131,615 | $31,789 | $56,238 | $30,732 |
| Free Cash Flow | -$153,341 | -$89,674 | -$76,457 | -$79,065 |